Separate terms with OR to return results that match either term.
 
Clear All
669 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS (Descending) Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9240 ixabepilone Ixempra 1mg Chemotherapy Antitumor Antibiotic Epothilones No 2007 Jan. 1, 2008 Dec. 31, 2013 No Longer Used
C9239 Temsirolimus Torisel 1 mg Chemotherapy Enzyme Inhibitor mTOR No 2007 Jan. 1, 2008 Dec. 31, 2008 No Longer Used
C9237 Lanreotide Acetate Somatuline Depot 1 mg Hormonal Therapy Somatostatin Analog No 2007 Jan. 1, 2008 In Use
C9235 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan. 1, 2007 Dec. 31, 2007 No Longer Used
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
C9215 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Feb. 12, 2004 Dec. 31, 2004 No Longer Used
C9214 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Feb. 26, 2004 Dec. 31, 2004 No Longer Used
C9213 Pemetrexed Alimta 10 mg Chemotherapy Antimetabolite Folic Acid Analog No 2004 Feb. 4, 2004 Dec. 31, 2004 No Longer Used
C9210 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan. 1, 2004 Dec. 31, 2004 No Longer Used
C9205 Oxaliplatin Eloxatin unspecified Chemotherapy Alkylating Agent Platinum Compound No 2002 July 1, 2003 Dec. 31, 2005 No Longer Used

Found 669 results in 1 millisecond — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.